Skip to main content
SpringerLink
Log in

Homocamptothecin-Daunorubicin Association Overcomes Multidrug-Resistance in Breast Cancer MCF7 Cells

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The multidrug-resistance (MDR) status of a novel camptothecin analogue, homocamptothecin (hCPT), was investigated in human colon adenocarcinoma HT29 cells, myelogenous leukemia K562 cells and breast carcinoma MCF7 cells. The cytotoxicity of hCPT was not sensitive to the MDR status in K562 cell lines. However, its cytotoxicity was altered by MRP1, but not Pgp, in naturally MRP1-expressing HT29 cells, and etoposide- and doxorubicin-resistant MCF7/VP and MCF7/DOX cells, respectively. These cells were sensitized to hCPT in presence of MK571, probenecid but not verapamil. These results led to consider hCPT as a substrate for MRP1 and a potential modulator of MRP1 activity. The relationship between the cytotoxic effect of anthracyclines and their nuclear localization had been previously demonstrated. We show that MRP1 mediated the daunorubicin (DNR) efflux in MCF7/VP and MCF7/DOX cells. The combination of sub-toxic doses of hCPT with DNR resulted in the potentiation of DNR activity, well-correlated with an increase in its nuclear accumulation in MCF7/VP cells. Simultaneous pattern was shown to provide higher cytotoxic response than sequential one. In agreement, hCPT increased also the DNR nuclear accumulation in low MRP1-expressing MCF7/DOX cells. However, the enhancement of cytotoxicity in the DNR-hCPT combination was poorly correlated with the nuclear concentration of DNR in MCF7/DOX cells. In addition to the increase in DNR accumulation, the potentiation of DNR activity by hCPT in MCF7/DOX cells implied a synergistic mechanism between both drugs. These data suggest that the present topoisomerase I/II inhibitors combination may be of clinical interest to overcome MDR phenotype in DNR-treated breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN: Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6: 133–146, 2001

    Google Scholar 

  2. Plosker GL, Faulds D: Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45: 788–856, 1993

    Google Scholar 

  3. Morjani H, Millot JM, Belhoussine R, Sebille S, Manfait M: Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance. Leukemia 11: 1170–1179, 1997

    Google Scholar 

  4. Germann UA: P-glycoprotein–A mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927–944, 1996

    Google Scholar 

  5. Hipfner DR, Deeley RG, Cole SPC: Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461: 359–376, 1999

    Google Scholar 

  6. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SPC, Doyle LA: Atypical multidrug resistance: breast cancer resistance protein messanger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91: 429–433, 1999

    Google Scholar 

  7. Belhoussine R, Morjani H, Lahlil R, Manfait M: Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and downregulation of mdr1 gene expression. Int J Cancer 73: 600–606, 1997

    Google Scholar 

  8. Benderra Z, Morjani H, Trussardi A, Manfait M: Characterization of H+ATPase-dependent activity of multidrug resistance-associated protein in homoharringtonine-resistant human leukemic K562 cells. Leukemia 12: 1539–1544, 1998

    Google Scholar 

  9. Legrand O, Zittoun R, Marie J-P: Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 13: 578–584, 1999

    Google Scholar 

  10. Sickic BI: Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 34: suppl 5, 40–47, 1997

    Google Scholar 

  11. Tan B, Piwnica-Worms D, Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450–458, 2000

    Google Scholar 

  12. Vezmar M, Georges E: Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol 59: 1245–1252, 2000

    Google Scholar 

  13. Gollapudi S, Kim CH, Tran BN, Sangha S, Gupta S: Probenecid reverses multidrug resistance in multidrug resistanceassociated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol 40: 150–158, 1997

    Google Scholar 

  14. D'Arpa P, Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163–177, 1989

    Google Scholar 

  15. Pommier Y, Pourquier P, Fan Y, Strumberg D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400: 83–106, 1998

    Google Scholar 

  16. Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore A-M, Harnett J, Pons D, Camara J, Bigg DCH: Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified analogues. J Med Chem 41: 5410–5419, 1998

    Google Scholar 

  17. Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonville L, Bailly C, Camara J, Lavergne O, Bigg DCH: Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 59: 2939–2943, 1999

    Google Scholar 

  18. Philippart P, Harper L, Chaboteaux C, Decaestecker C, Bronckart Y, Gordover L, Lesueur-Ginot L, Malonne H, Lavergne O, Bigg DCH, Da Costa PM, Kiss R: Homocamp tothecin, an E-ring modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res 6: 1557–1562, 2000

    Google Scholar 

  19. Zhou D-C, Ramond S, Viguie F, Faussat A-M, Zittoun R, Marie J-P: Sequential emergence of MRP-and MDR1-gene over-expression as well as MDR1-gene translocation in homoharrringtonine-selected K562 human leukemia cell lines. Int J Cancer 65: 365–371, 1996

    Google Scholar 

  20. Fairchild CR, Ivy SO, Kao-Shan C, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH, Goldsmith ME: Isolation of amplified and over-expressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47: 5141–5148, 1987

    Google Scholar 

  21. Schneider E, Horton JK, Yang C-H, Nakagawa M, Cowan KH: Multidrug resistance-associated protein (MRP) gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152–158, 1994

    Google Scholar 

  22. Chomczynski P, Sacchi N: Single-step-method of RNA isolation by acid guanidinium-thiocynate-phenolchloroform extraction. Anal Biochem 162: 156–159, 1987

    Google Scholar 

  23. Burdow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD: Expression of the multidrug resistanceassociated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54: 5036–5040, 1994

    Google Scholar 

  24. Gigli M, Doglia S, Millot JM, Valentini L, Manfait M: Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry. Biochim Biophys Acta 950: 13–20, 1988

    Google Scholar 

  25. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85, 1979

    Google Scholar 

  26. Millot J-M, Rasoanaivo TDW, Morjani H, Manfait M: Role of aclacinomycin A-doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells. Br J Cancer 60: 678–684, 1989

    Google Scholar 

  27. Morjani H, Belhoussine R, Lahil R, Manfait M: Pirarubicin nuclear uptake does not correlate with its induced cell death effect during reversal of multidrug resistance by quinine in human K562 and CEM leukemic cells. Eur J Heamatol 61: 240–249, 1998

    Google Scholar 

  28. Lavie Y, Cao H-T, Volner A, Lucci A, Han T-Y, Geffen V, Giuliano AE, Cabot MC: Agents that reverse multidrug resistance, tamofixen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272: 1682–1687, 1997

    Google Scholar 

  29. Lucci A, Han T-Y, Giuliano AE, Cabot MC: Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 86: 300–311, 1999

    Google Scholar 

  30. Kok JW, Babia T, Filipeanu CM, Nelmans A, Egea G, Hoekstra D: PDMP blocks Brefeldin A-induced retrograde membrane transport from Golgi to ER: evidence for involvement of calcium homeostasis and dissociation from sphingolipid metabolism. J Cell Biol 142: 25–38, 1998

    Google Scholar 

  31. Belhoussine R, Morjani H, Millot JM, Sharonov S, Manfait M: Confocal scanning microspectrofluorometry reveals specific anthracycline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells. J Histochem Cytochem 46: 1369–1376, 1998

    Google Scholar 

  32. Merlin J-L, Bour-Dill C, Marchal S, Ramacci C, Poullain M-G, Giroux B: Modulation of daunorubicin cellular resistance by combination of p-glycoprotien blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles. Cytometry 41: 62–72, 2000

    Google Scholar 

  33. Chauvier D, Chourpa I, Bigg DCH, Manfait M: Kinetics of in vitro hydrolysis of homocamptothecins as measured by fluorescence. Ann NY Acad Sci 922: 314–316, 2000

    Google Scholar 

  34. Lavergne O, Demarquay D, Bailly C, Lanco C, Rolland A, Huchet M, Coulomb H, Muller N, Baroggi N, Camara J, Le Breton C, Manginot E, Cazaux J-B, Bigg DCH: Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem 43: 2285–2289, 2000

    Google Scholar 

  35. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF: Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039–6044, 1991

    Google Scholar 

  36. Jansen WJ, Huschler TM, Van Ark-Otte J, Giaccone G, Pinedo HM, Boven E: CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer 77: 359–365, 1998

    Google Scholar 

  37. Jonsson E, Fridborg H, Csoka K, Dhar S, Sundstrom C, Nygren P, Larsson R: Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76: 211–219, 1997

    Google Scholar 

  38. Chen Z-S, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, Akiyama S-I: ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55: 921–928, 1999

    Google Scholar 

  39. Laroche-Clary A, Larrue A, Robert J: Down-regulation of bcr-abl and bcl-Xl expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors. Biochem Pharmacol 60: 1823–1828, 2000

    Google Scholar 

  40. Perkins C, Kim CN, Fang G, Bhalla KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-XL. Blood 95: 1014–1021, 2000

    Google Scholar 

  41. Yang C-HJ, Horton JK, Cowan KH, Schneider E: Crossresistance to camptothecin analogues in mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 55: 4004–4009, 1995

    Google Scholar 

  42. Chen Z-S, Sumizawa T, Furukawa T, Ono K, Tani A, Komatsu M, Akiyama S-I: An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. Cancer Lett 138: 13–22, 1999

    Google Scholar 

  43. Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G, Schellens JHM: Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human resistance in a human ovarian cancer cell line. Br J Cancer 77: 7645–1652, 1998

    Google Scholar 

  44. Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Friedberg TH, Smith G, Wolf H, Ethell B, Burchell B, Smyth JF, Jodrell DI: Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells, contribution of drug transport proteins. Proc Am Ass Cancer Res 42: 278, poster 1497, 2001

    Google Scholar 

  45. Kaufmann SH: Antagonism between camptothecin and topoisomerase II-targeted chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129–1136, 1991

    Google Scholar 

  46. Bertrand R, O'Connor PM, Kerrigan D, Pommier Y: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A: 743–748, 1992

    Google Scholar 

  47. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K: Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50: 760–776, 1992

    Google Scholar 

  48. Eder JP, Chan V, Wong J, Wong YW, Ara G, Northey D, Rivzi N, Teichir BA: Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 42: 327–335, 1998

    Google Scholar 

  49. D'Arpa P, Beardmore C, Liu LF: Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919–6924, 1990

    Google Scholar 

  50. Tolcher AW, O'shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hafim F, Gress R, Goldspiel B, Noone MN, Brewster LR, Gossard MR, Cowan KH: A phase I of topotecan followed by doxorubicin in patient with advanced malignacies. Clin Cancer Res 3: 755–760, 1997

    Google Scholar 

  51. Ryan CW, Fleming GF, Janish L, Ratain MJ: A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol 23: 297–300, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UFR Pharmacie, Unité MéDIAN, CNRS FRE2141, IFR53, Reims, France

    David Chauvier, Hamid Morjani & Michel Manfait

Authors
  1. David Chauvier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamid Morjani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel Manfait
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chauvier, D., Morjani, H. & Manfait, M. Homocamptothecin-Daunorubicin Association Overcomes Multidrug-Resistance in Breast Cancer MCF7 Cells. Breast Cancer Res Treat 73, 113–125 (2002). https://doi.org/10.1023/A:1015244604336

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015244604336

Search

Navigation